The White House announced most‑favored‑nation (MFN) pricing agreements with nine biopharmas as part of a broader push to align U.S. drug prices more closely with international levels. The administration said only three of the original 17 targeted companies — AbbVie, Johnson & Johnson and Regeneron — have yet to finalize terms. The MFN deals focus on Medicaid and cash prices and accompany proposed mandatory Medicare demonstrations. Industry and policy observers expect legal and commercial pushback as these pricing initiatives move toward implementation. Source: White House announcements and industry reporting.